1 January 2021 in Urology Research and Practice
Objective: Sacral neuromodulation (SNM) is an advanced treatment option for patients with refractory overactive bladder (OAB) symptoms, urinary retention, and bowel disorders; it is usually performed in 2 separate procedures. This study aims to determine a cohort’s progression rate from stage 1 to 2 and predict factors for progression and unplanned device removal or revision. Material and methods: A retrospective review was conducted in patients who underwent SNM at a single institution between June 2012 and May 2019. Progression rates from stage 1 to 2, patient characteristics, and indications for unplanned SNM removal or revision were recorded. Chi-square, Mann-Whitney U, and Fisher’s exact tests were used for data analysis. Results: A total of 128 patients underwent SNM for 1 or more of the following diagnoses: OAB (n=103), urinary retention (n=15), neurogenic bladder dysfunction (n=4), fecal incontinence (n=2), and constipation (n=4). The progression rate to stage 2 was 92.2% (118/128). Patients who failed to progress to stage 2 had additional diagnoses other than OAB, such as urinary retention or bowel disorders (p=0.007). Fifteen patients (12.7%) required SNM removal or revision within 4 years of surgery. Among these patients, the body mass index was significantly lower (p=0.036). Conclusion: Most patients (92.2%) progressed to stage 2. Patients with only OAB symptoms had a higher progression rate to stage 2. Single full-stage procedures may be considered in select patients to reduce morbidity, time, and costs. Cite this article as: Feldkamp A, Amasyalı AS, Groegler J, Jellison F, Staack A. Evaluation of progression from first to second stage sacral neuromodulation and unplanned device removal. Turk J Urol 2021; 47(1): 58-65.
30 March 2021 in Journal of Clinical Urology
Sacral neuromodulation (SNM) is a Food and Drug Administration–approved treatment option for urinary urgency and fecal incontinence. Fluoroscopic imaging is used at various steps during lead placement, which exposes the operating room staff and patient to the harmful effects of radiation. The aim of this study is to describe a reduced radiation technique during lead placement for treatment with SNM. A retrospective cohort of 51 consecutive patients who underwent lead insertion and SNM placement at a single academic institution were investigated. Reduced fluoroscopy (RF; n=11) involved C-arm settings to 1 pulse/second and an activated “low-dose” setting, while conventional fluoroscopy (CF; n=40) involved 30 pulses/second and a deactivated “low-dose” setting. The automatic brightness control and collimation were used optionally in both groups. Comparison of imaging quality, fluoroscopy settings, and radiation exposure during RF and CF was performed. RF settings resulted in significant reduction of radiation compared to CF settings, including the fluoroscopy time (8.61 vs. 48.16 seconds; p<0.001), dose (2.66 vs. 26.25 mGy; p=0.001), and current (1.67 vs. 4.18 mAs; p<0.001). There was no significant difference in total operative time (59.18 vs. 61.33 minutes; p=0.77) and the rate of progression from stage 1 to stage 2 during follow-up (75% vs. 84%; p=0.55). Lead placement for treatment with SNM can be achieved using RF settings without compromising clinical outcomes. Applying the RF technique reduces overall radiation exposure to the patient and the operating room staff. Further validation of RF in a larger prospective cohort study is needed. Level 4.